Miltenyi Biotec-tested panel 35 (MBTP 35)
This application protocol describes the characterization of human monocytes, neutrophils, eosinophils, and T, B, and NK lymphocyte populations as well as CD4+, CD8+, and CD56+CD3+ T cell subsets in human ovarian carcinoma using flow cytometry. Prior to staining the tumor was dissociated employing the gentleMACS™ Octo Dissociator with Heaters and Tumor Dissociation Kit, human.
|Specificity||Clone||Purpose||Fluorochrome||Detection filter (nm) (laser)|
|CD3||REA613||T cells||PE||579/34 (blue)|
|CD4||REA623||T helper cells||Vio® Bright 667||667/30 (red)|
|CD8||REA734||Cytotoxic T cells||APC-Vio 770||785/62 (red)|
|CD16||REA423||Neutrophils, eosinophils||Vio Bright 515||525/50 (blue)|
|CD19||REA675||B cells||PE-Vio 770||785/62 (blue)|
|CD56||REA196||NK cells||Vio Bright 515||525/50 (blue)|
|7-AAD Staining Solution||-||Viability||-||667/30 (blue)|
Unless otherwise specifically indicated, Miltenyi Biotec products and services are for research use only and not for therapeutic or diagnostic use.
If not otherwise specified, all marks displayed on the Miltenyi Biotec Internet site and documents are subject to the trademark rights of Miltenyi Biotec, including each of Miltenyi Biotec's primary brands, its model name plates, and its corporate logos and emblems.
For copyright note and a complete list of trademarks visit www.miltenyibiotec.com/legalnotes.
Seems like you are coming from USA!
Do you want to visit our website in your country?